Source: Photo.com
On January 5, Full-Life announced the closing of a $63.3 million funding round led by Prosperity7 Ventures, a fund of Aramco Ventures. Full-Life is an international radiopharmaceutical company, and its last round of financing was led by Sequoia China.
According to the official website, Prosperity7 Ventures is a diversified growth fund with a scale of about $1 billion officially launched in 2022 by Aramco Ventures, the corporate venture capital arm of Saudi Arabian National Oil Company, and currently has a Chinese team of about 15 people.
It is reported that the Prosperity7 Ventures China team has completed 15 investments in the past 18 months, and with this year's investment, it has invested in more than 20 companies in China, accounting for more than half of the global portfolio.
In addition, it is worth noting that Prosperity7 also announced another Chinese investment on December 27, 2023 - leading the B round of financing of Juhe Biotech exceeding 100 million yuan. The latter focuses on the field of women's health and has successfully launched methylation detection products for early screening of gynecological tumors.
So far, the Middle Eastern fund has invested in two Chinese medical companies in a row, both in the direction of oncology.
Cancer is one of the most urgent human health problems
Tumor refers to the new organism formed by the body's uncontrolled local tissue cells in the body under the action of various tumorigenic factors, which generally manifests as a mass. Tumors are divided into two categories: benign and malignant, benign tumors grow slowly and have little impact on the human body; Malignant tumors, commonly known as cancer, tend to grow rapidly, and are aggressive (infiltrating into surrounding tissues) and metastasis, which is the biggest medical and health problem facing human beings at present, and it is also the most malignant human disease. Cancer has the characteristics of high mortality, poor prognosis, and expensive treatment, and cancer patients usually need to endure great physical suffering, which is one of the most urgent human medical and health problems to be solved.
According to data from GLOBOCAN, the American Chemical Society, the National Council for Clinical Research, and Frost & Sullivan, lung cancer, breast cancer, colorectal cancer, skin cancer, prostate cancer, gastric cancer, liver cancer, lymphoma, esophageal cancer, and cervical cancer are the top ten cancers ranked by incidence in the world.
There are a total of 4,531 oncology drug R&D pipelines in mainland China
It is reported that anti-cancer drugs can be roughly divided into chemotherapy drugs, targeted drugs, immune checkpoint inhibitors (referred to as immunotherapy), etc. Among them, in recent years, there are three main types of anti-cancer drugs in mainland China: targeted therapy drugs, anti-angiogenic drugs, and immune checkpoint inhibitors (immunotherapy).
According to data from ClinicalTrials, as of May 27, 2022, there were 4,531 R&D pipelines of oncology drugs in mainland China. From the perspective of the timeline, the current R&D pipeline of oncology drugs in mainland China is mainly concentrated in the past three years. In 2021, the R&D pipeline of oncology drugs in mainland China reached a peak of 1,459 in recent years. In 2022, the number of R&D pipelines of oncology drugs in mainland China will be 721.
The global oncology drug market size will be around $391.3 billion in 2030
The global oncology drugs market will continue to grow at a high rate due to the aging population and the increasing incidence of cancer. In addition, with the successful development of new targeted drugs and new treatments such as tumor immunity, tumor treatment methods are also changing, which is expected to greatly promote the growth of the tumor drug market. In this context, Frost & Sullivan predicts that the global oncology drug market will be about $391.3 billion in 2030, accounting for 18.8% of the total drug market.
Li Xiaomei, chief physician of the Department of Radiation Oncology of the Provincial Hospital Affiliated to Shandong First Medical University, suggested that everyone should develop good living Xi, and at the same time, everyone should be the first responsible person for their own health, pay attention to cancer prevention and early screening, especially high-risk groups, and pay more attention to "changing the trajectory of life" through early screening. "Cancer is not as scary as we think, and some cancers can be prevented by staying away from tobacco and alcohol, living regularly, eating a reasonable diet, and maintaining a healthy mindset. At the same time, some tumors such as esophageal cancer, gastric cancer, colorectal cancer, and cervical cancer can be treated early through screening, early diagnosis, and early treatment, and even cure. Li Xiaomei said that early screening and early diagnosis of tumors is the foundation for improving the survival rate.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Market Prospect and Investment Strategic Planning Analysis Report of China's Anti-tumor Drug Industry" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, IPO working paper consulting, etc. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers.